Published in:
Open Access
01-12-2018 | Research article
Annexin A1 in plasma from patients with bronchial asthma: its association with lung function
Authors:
Sun-Hye Lee, Pureun-Haneul Lee, Byeong-Gon Kim, Hyun-Jeong Seo, Ae-Rin Baek, Jong-Sook Park, June-Hyuk Lee, Sung-Woo Park, Do-Jin Kim, Choon-Sik Park, An-Soo Jang
Published in:
BMC Pulmonary Medicine
|
Issue 1/2018
Login to get access
Abstract
Background
Annexin-A1 (ANXA1) is a glucocorticoid-induced protein with multiple actions in the regulation of inflammatory cell activation. The anti-inflammatory protein ANXA1 and its N-formyl peptide receptor 2 (FPR2) have protective effects on organ fibrosis. However, the exact role of ANXA1 in asthma remains to be determined. The aim of this study was to identify the role of ANXA1 in bronchial asthma.
Methods
In mice sensitized and challenged with ovalbumin (OVA-OVA mice) and mice sensitized with saline and challenged with air (control mice), we investigated the potential links between ANXA1 levels and bronchial asthma using ELISA, immunoblotting, and immunohistochemical staining. Moreover, we also determined ANXA1 levels in blood from 50 asthmatic patients (stable and exacerbated states).
Results
ANXA1 protein levels in lung tissue and bronchoalveolar lavage fluid were significantly higher in OVA-OVA mice compared with control mice. FPR2 protein levels in lung tissue were significantly higher in OVA-OVA mice compared with control mice. Plasma ANXA1 levels were increased in asthmatic patients compared with healthy controls. Plasma ANXA1 levels were significantly lower in exacerbated patients compared with stable patients with bronchial asthma (p < 0.05). The plasma ANXA1 levels in controlled asthmatic patients were correlated with forced expiratory volume in 1 s (FEV1) (r = − 0.191, p = 0.033) and FEV1/forced vital capacity (FVC) (r = −0.202, p = 0.024).
Conclusion
These results suggest that ANXA1 may be a potential marker and therapeutic target for asthma.